If these epitopes are restricted to sites of glycosylation, one could consider the possibility of these antibodies modifying the clinical course of podocyte cell body-based MCD mechanisms in a ZHX2 hypomorph state with slit diaphragm-related signals seen classically with FSGS pathophysiology (Fig. 1, bottom and middle). Here, ZHX2 is linked to focal segmental glomerulosclerosis.